IQAI - LLC ("IB"), has entered into sales agreement with CorTechs Labs4 Nov 2020 22:27
IQ-AI Ltd (LON: IQAI), is pleased to announce that the Company's subsidiary, Imaging Biometrics®, LLC ("IB"), has entered into a non-exclusive business development and sales agreement with CorTechs Labs ("CorTechs"), a global leader in quantitative analysis of brain structures and lesions. The agreement with CorTechs means that IQ-AI's products will benefit from an extended and immediate sales representation in the US and other international markets. The agreement expands CorTechs' portfolio to include IB software's exclusive algorithms that advance clinical understanding of brain tumor pathology by quantitatively distinguishing tumor progression from confounding MR or CT image artifacts.
And...(something that was not going to happen!)
B StoneChecker® analysis software is in the final stages of FDA clearance for distribution in the US and will also be added to the CorTechs' portfolio, internationally.
David Smith, commented: "For the first time IQ-AI's full range of products will have direct sales representation worldwide. We are very excited about the shared revenue potential of this agreement. CorTechs Labs has a well established and rapidly growing sales and marketing team who can introduce IB's portfolio to their existing and new clients."
So the sales channel set and already in progress - expect orders very very soon - as per today RNS following FDA approval.
You can say multi bags again. Hopefully we can hit 25p tomorrow, and set the scene for 100p as we go into next year.